Sunday, September 13, 2026
RSS

Inside BCI

Brain-Computer Interface Industry News
Industry News Research Policy Opinion Market Moves
About Directory Glossary
Market Moves

Three Chinese BCI operators are in the IPO queue at once

Three Chinese brain-computer interface operators are simultaneously moving through IPO processes on two exchanges. Neuracle Medical Technology (博睿康技术（上海）股份有限公司) is the leader: its Shanghai STAR Market prospectus was accepted 11 June 2026 with a planned RMB 2.5 billion (~US$345M) raise. Neuracle received China's first commercial invasive BCI approval from NMPA in March 2026 (NEO-ONE SCI for spinal cord injury). BrainCo (强脑科技) filed a confidential Hong Kong Exchange application in January 2026 (joint sponsors CICC and UBS), with the September 2026 pricing calendar showing no imminent hearing. Arfysica Innovation (术理创新), led by female founder Wang Wei, registered STAR Market pre-IPO tutoring in early September 2026 with Huatai United Securities, entering the pipeline three months behind Neuracle at the earliest stage. Neuracle's disclosed prospectus reveals RMB 108 million 2025 revenue, all from non-invasive EEG systems, with the NEO invasive product still at zero commercial revenue and 32 patients implanted by end-2025.

Sep 14, 2026 · 9 min read

Policy & Regulation

Cambridge-led security team names five attack families that break AI-powered brain-computer interfaces

A team led by Zahra Tarkhani (Microsoft), Georgios Akkogiounoglou (KTH Royal Institute of Technology), Lorena Qendro (Nokia Bell Labs), Isabel Tscherniak (TU Munich), and senior author Anil Madhavapeddy (University of Cambridge) published NERVE Attacks: Breaking AI-Powered Brain-Computer Interfaces on arXiv on 8 September 2026. The paper introduces a taxonomy of five attack families that together span the complete BCI signal chain: Neuro-mimetic Forgery, Evasion via Desynchronization, Replay-based Hijacking, Vein Tapping, and Embedded Backdoors. It releases EEGle, an AI-assisted extensible framework for systematic BCI security analysis, and reports 17 novel neuro-specific attack instances plus a stealth-effectiveness spectrum for BCI backdoor design. The submission lands four days after Germany's outgoing federal data protection commissioner used the BfDI's annual Bonn conference on 4 September 2026 to press for tighter European handling of neurodata, and one day after four senior clinician-scientists published a Comment in Nature Neuroscience setting out four ethical priorities for implantable BCI research. The empirical attack surface has now caught up with the governance framing.

Sep 13 · 6 min read

Policy & Regulation

Plexon settles $1.7M US export case for shipping brain-recording equipment to China's People's Liberation Army

The US Department of Commerce Bureau of Industry and Security (BIS) announced on 14 August 2026 an administrative enforcement settlement with Dallas, Texas neural-instrumentation maker Plexon, Inc. over eight unlicensed exports between 10 February 2022 and 30 August 2023 to the Academy of Military Medical Sciences (AMMS), the People's Liberation Army's biomedical research arm and a party on the BIS Entity List since December 2021. The shipments comprised eight OmniPlex Neural Recording Data Acquisition Systems and accessories, valued at approximately US$178,721. The civil penalty is US$1.7 million, suspended in full for five years contingent on Plexon completing an external export-compliance audit and committing no further violations. AMMS was added to the Entity List in part for supporting Chinese military end uses including 'purported brain-control weaponry.' The settlement is the first BIS enforcement action publicly involving commercial brain-computer interface research instrumentation, and lands eight years after BIS's November 2018 emerging-technology framework flagged BCI and AI for brain modeling as candidate export-control categories.

Sep 11 · 6 min read

Market Moves

ONWARD Medical crosses seven ARC-BCI implants as ARC-EX commercial revenue grows 240 percent in H1

Dutch-Swiss neurotech ONWARD Medical (Euronext ONWD) reported First Half 2026 results on 9 September 2026 with total revenue of EUR 4.2 million (up from EUR 1.2 million H1 2025), ARC-EX external spinal-stimulator commercial revenue up 240 percent to EUR 3.4 million, and cumulative ARC-BCI Therapy participants now at seven, with two additional implants completed in the half. ARC-BCI is ONWARD's flagship platform pairing the CEA/Clinatec WIMAGINE 64-electrode epidural cortical brain-computer interface (exclusive-licensed 15 October 2024) with the ARC-IM implantable spinal cord stimulator. ONWARD is accepted into the FDA Total Product Life Cycle Advisory Program for ARC-BCI. Cash position was EUR 81.5 million at 30 June 2026 following the April 2026 EUR 40.6 million equity raise led by EQT Life Sciences and a new BlackRock debt facility up to EUR 50 million. ARC-EX (FDA De Novo cleared December 2024) is now available in more than 130 US clinics and shipped 159 systems in the half.

Sep 10 · 6 min read

Industry News

Apple acquires neural-sensor startup Sonera Magnetics

Apple's acquisition of Berkeley-based magnetic-sensor startup Sonera Magnetics, closed in May 2026 and disclosed publicly on 8 September 2026 via the European Commission's Digital Markets Act acquisitions database, is the company's first move from hosting third-party brain-computer interface signals to owning proprietary neural-sensor IP. Sonera builds solid-state acoustically-driven ferromagnetic resonance (ADFMR) magnetometers, a room-temperature alternative to SQUID-based magnetoencephalography (MEG). The company raised US$11 million in seed financing in September 2023 from a lead-heavy syndicate including Founders Fund, Benchmark, Amplify Partners, IVP, Craft Ventures, and 8VC. Deal terms were not disclosed. Sonera's website was taken offline post-acquisition. Apple's prior BCI-adjacent moves were the AirPods ear-canal biosignal patent (filed January 2023), the BCI HID accessibility protocol for iOS 26, iPadOS 26 and visionOS 26 launched with Synchron on 13 May 2025, and hosting of Cognixion's non-invasive EEG clinical trial on Vision Pro from October 2025. Owning Sonera's magnetic-sensor IP puts Apple directly against Meta's Neural Band (surface EMG) and the non-surgical BCI operator field (Merge Labs ultrasound, Subsense nanoparticle, Neurable EEG earbuds).

Sep 9 · 6 min read

Policy & Regulation

Four senior BCI neurosurgeon-scientists use Nature Neuroscience to press for tighter research ethics as implant numbers scale

Four clinician-scientists from Mayo Clinic, University College London, and Sichuan University published a Comment in Nature Neuroscience on 7 September 2026 setting out four ethical priorities for implantable brain-computer interface research: separating research participation from patient care, ensuring long-term support for study participants, avoiding disproportionate risks to participants for benefits realised mainly by others, and grounding research in meaningful clinical purpose. Lead author Kai J. Miller (Mayo Clinic) is the corresponding author. Senior author Gerwin Schalk (West China Hospital, Sichuan University) is the second corresponding author. Co-author Harith Akram (UCL Queen Square) declares a conflict of interest as Chief Investigator of Neuralink's GB-PRIME UK study. The Comment lands one day after Germany's outgoing federal data protection commissioner pressed Europe for tighter rules on bidirectional BCI, and ten months after UNESCO's General Conference adopted the first global standard on the ethics of neurotechnology in November 2025.

Sep 8 · 6 min read

Policy & Regulation

Germany's data protection commissioner presses Europe for tighter rules on bidirectional brain-computer interfaces

Prof. Dr. Louisa Specht-Riemenschneider, the outgoing German Federal Data Protection and Freedom of Information Commissioner (BfDI), used a BCI-themed academic conference at the University of Bonn on 4 September 2026 to press for tighter European handling of neural data. Her formal underpinning is a Berlin Group Working Paper on Emerging Neurotechnologies published on 15 May 2025 through BfDI, which invokes GDPR Article 9 (health and biometric data) and the EU AI Act (Article 5 subliminal-manipulation ban, Annex III high-risk classification for medical BCI) as existing legal ground. The intervention lands one month before Specht-Riemenschneider steps down for health reasons on 30 September 2026. Her Bundestag-elected successor Prof. Dr. Moritz Hennemann of Freiburg takes office on 1 October 2026, and his own position on neurodata is not publicly disclosed.

Sep 6 · 6 min read

Industry News

Ray Kurzweil joins nanoparticle-BCI startup Subsense as Product and Vision Advisor

Ray Kurzweil, the futurist and inventor who has argued for two decades that brain-computer interfaces will arrive through molecular-scale machines rather than through skull-drilled implants, has joined Palo Alto-based Subsense as Product and Vision Advisor. Subsense unveiled the appointment on the evening of 2 September 2026 at its Palo Alto headquarters. Subsense, founded 2022 by CEO Tetiana Aleksandrova and Artem Sokolov, is developing a non-surgical BCI based on intranasally-delivered nanoparticles paired with a wearable magnetic-coil headset. The company has raised US$27 million in seed financing led by Sokolov's Golden Falcon Capital and remains in preclinical mouse-model work. The appointment lands one week after Merge Labs and Butterfly Network's chip-supply deal established the ultrasound-BCI industrial base, and adds a molecular modality to the non-surgical BCI landscape.

Sep 4 · 5 min read

Market Moves

NMPA clears Tiankai Suishi's non-invasive EEG cap for cognitive-impairment diagnosis

China's National Medical Products Administration approved a non-invasive EEG-cap diagnostic device made by Tianjin-based Tiankai Suishi Intelligent Technology on 19 August 2026 for assessing cognitive impairment. The device sits in the diagnostic tier of China's growing brain-computer interface pipeline: Class II non-invasive rather than the Class III invasive category cleared by Neuracle in March 2026. Tiankai Suishi is a Tianjin University-linked startup founded 2023, led by Gu Bin, with a depression-diagnosis product also filed with NMPA. The approval extends China's Industrial Builder posture from a single invasive-BCI flagship into diagnostic-device territory anchored on the country's ageing-population indications: Alzheimer's, schizophrenia-linked cognitive dysfunction, and depression.

Sep 3 · 4 min read